Rapid Acting Antidepressants

Ronald Duman is at Yale University School of Medicine, CT, USA John Krystal is at Yale University, CT, USA

• Part I – Neurobiology of ketamine effects Effects of ketamine and other rapidly acting antidepressants on hippocampal excitatory and inhibitory transmissionAllie J. Widman and Lori L. McMahonAntidepressant mechanisms of ketamine: Focus on GABAergic inhibitionBernhard Luscher, Mengyang Feng and Sarah J. JeffersonThe role of eEF2 kinase in the rapid antidepressant actions of ketamineKanzo Suzuki and Lisa M. MonteggiaPart II – The rapid therapeutic effects of ketamineClinical overview of NMDA-R antagonists and clinical practicePasha A. Davoudian and Samuel T. WilkinsonKetamine for depression clinical issuesSyed Z. Iqbal and Sanjay J. MathewChronic stress pathology and ketamine-induced alterations in functional connectivity in major depressive disorder: An abridged review of the clinical evidence Lynnette A. Averill, Samar Fouda, James W. Murrough and Chadi G. AbdallahNeurobiological biomarkers of response to ketamineBashkim Kadriu, Elizabeth D. Ballard, Ioline D. Henter, Stephen Murata, Nimesha Gerlus and Carlos A. Zarate JrRelapse prevention in treatment resistant major depressive disorder with rapid-acting antidepressantsJaskaran B. Singh, Maggie Fedgchin, Ella J. Daly and Wayne C. DrevetsThe emergence of ketamine as a novel treatment for posttraumatic stress disorderAdriana Feder, Sarah B. Rutter, Daniela Schille and Dennis S. CharneyPart III – Novel rapid-acting antidepressant mechanisms related to ketaminemGlu2/3 receptor as a novel target for rapid acting antidepressantsShigeyuki ChakiInvolvement of muscarinic receptor mechanisms in antidepressant drug actionJeffrey M. Witkin, Jodi L. Smith, Lalit K. Golani, Emily A. Brooks and Anna E. MartinThe antidepressant efficacy of the muscarinic antagonist scopolamine: Past findings and future directions Wayne C. Drevets, Anindya Bhattacharya and Maura L. Furey